Andrea Newkirk
Stock Analyst at Goldman Sachs
(0.77)
# 4,123
Out of 5,058 analysts
43
Total ratings
43.5%
Success rate
-6.3%
Average return
Main Sectors:
Stocks Rated by Andrea Newkirk
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Reiterated: Sell | $321 → $368 | $541.51 | -32.04% | 2 | Oct 15, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Sell | $7 | $8.17 | -14.32% | 2 | Sep 30, 2026 | |
| KOD Kodiak Sciences | Reiterated: Hold | $103 | $88.12 | +16.89% | 2 | Sep 29, 2026 | |
| ABCL AbCellera Biologics | Initiated Coverage: Hold | $13 | $12.68 | +2.52% | 1 | Sep 24, 2026 | |
| ALKS Alkermes | Initiated Coverage: Hold | $26 → $50 | $40.10 | +24.69% | 2 | Sep 24, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Initiated Coverage: Hold | $85 → $74 | $58.50 | +26.50% | 3 | Sep 24, 2026 | |
| INSM Insmed | Initiated Coverage: Buy | $230 → $188 | $99.21 | +89.50% | 7 | Sep 24, 2026 | |
| IOVA Iovance Biotherapeutics | Initiated Coverage: Buy | $2 → $15 | $14.72 | +1.90% | 4 | Sep 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Buy | $154 → $337 | $214.42 | +57.17% | 2 | Sep 24, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $194 → $441 | $330.00 | +33.64% | 3 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $540 → $704 | $459.81 | +53.11% | 3 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $16 | $9.88 | +61.94% | 1 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 → $267 | $189.26 | +41.08% | 2 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 → $116 | $70.99 | +63.40% | 4 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $21 | $25.48 | -17.58% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.17 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.34 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.20 | n/a | 1 | Dec 4, 2024 |
United Therapeutics
Oct 15, 2026
Reiterated: Sell
Price Target: $321 → $368
Current: $541.51
Upside: -32.04%
Sagimet Biosciences
Sep 30, 2026
Reiterated: Sell
Price Target: $7
Current: $8.17
Upside: -14.32%
Kodiak Sciences
Sep 29, 2026
Reiterated: Hold
Price Target: $103
Current: $88.12
Upside: +16.89%
AbCellera Biologics
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $13
Current: $12.68
Upside: +2.52%
Alkermes
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $26 → $50
Current: $40.10
Upside: +24.69%
Arrowhead Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $85 → $74
Current: $58.50
Upside: +26.50%
Insmed
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $230 → $188
Current: $99.21
Upside: +89.50%
Iovance Biotherapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $2 → $15
Current: $14.72
Upside: +1.90%
Jazz Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $154 → $337
Current: $214.42
Upside: +57.17%
Krystal Biotech
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $194 → $441
Current: $330.00
Upside: +33.64%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $540 → $704
Current: $459.81
Upside: +53.11%
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $16
Current: $9.88
Upside: +61.94%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $38 → $267
Current: $189.26
Upside: +41.08%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $68 → $116
Current: $70.99
Upside: +63.40%
Nov 7, 2025
Reiterated: Hold
Price Target: $19 → $21
Current: $25.48
Upside: -17.58%
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $6.17
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $19.34
Upside: n/a
Dec 4, 2024
Rated: Hold
Price Target: n/a
Current: $3.20
Upside: n/a